Literature DB >> 14735336

Pruritus in a patient with advanced cancer successfully treated with continuous infusion of granisetron.

Giampiero Porzio1, Federica Aielli, Filomena Narducci, Katia Cannita, Domenico Piccolo, Paolo Marchetti.   

Abstract

We present a case of a patient with advanced cancer affected by severe pruritus not related with cholestasis and/or opioid treatment successfully treated with subcutaneous continuous infusion of granisetron (3 mg/24 h diluted in normal saline via a disposable elastomeric infusion device). Confirmatory studies with a control group are warranted to confirm these preliminary results.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14735336     DOI： 10.1007/s00520-003-0581-2

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  7 in total

Review 1.  Understanding pruritus in systemic disease.

Authors:  M Krajnik; Z Zylicz
Journal:  J Pain Symptom Manage       Date:  2001-02       Impact factor: 3.612

2.  Severe pruritus in a haemodialysed patient: dramatic improvement with granisetron.

Authors:  M P Albares; I Betlloch; J Guijarro; G Vergara; J C Pascual; R Botella
Journal:  Br J Dermatol       Date:  2003-02       Impact factor: 9.302

3.  A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch.

Authors:  M Murphy; D Reaich; P Pai; P Finn; A J Carmichael
Journal:  Br J Dermatol       Date:  2003-02       Impact factor: 9.302

Review 4.  Pruritus in cancer patients.

Authors:  V Lidstone; A Thorns
Journal:  Cancer Treat Rev       Date:  2001-10       Impact factor: 12.111

5.  Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.

Authors:  L A Trissel; D L Gilbert; J F Martinez
Journal:  Am J Health Syst Pharm       Date:  1997-01-01       Impact factor: 2.637

6.  Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron.

Authors:  Harald Schwörer; Heinz Hartmann; Giuliano Ramadori
Journal:  Pain       Date:  1995-04       Impact factor: 6.961

7.  Stability of granisetron hydrochloride in a disposable elastomeric infusion device.

Authors:  K C Chung; A Chin; M A Gill
Journal:  Am J Health Syst Pharm       Date:  1995-07-15       Impact factor: 2.637
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.